- Poster presentation
- Open Access
Strong association between hla-a*02:06 and acetaminophen-related stevens-johnson syndrome with severe mucosal involvements in the Japanese
© Ueta et al; licensee BioMed Central Ltd. 2014
- Published: 18 July 2014
- Oral Cavity
- Carrier Frequency
- Mucous Membrane
- Specific Drug
Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucous membranes of, for example, the ocular surface, oral cavity, and genitals. They are rare but often associated with inciting drugs. Cold medicines including non-steroidal anti-inflammatory drugs (NSAIDs) and multi-ingredient cold medications are reported to be important inciting drugs. We investigated the association between HLA genotypes and cold medicine-related SJS/TEN (CM-SJS/TEN) with severe mucosal involvement such as severe ocular surface complications (SOC). We also investigated the association between HLA genotypes and acetaminophen-related SJS/TEN in patients with CM-SJS/TEN with SOC.
Japanese acetaminophen-related SJS/TEN patients consist of 59 patients, they were among the 131 CM-SJS/TEN with SOC. While the specific drugs were not named by all 131 patients, 59 (45.0%) were known to have taken medicines containing acetaminophen. The diagnosis of SJS/TEN with SOC was based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions, and the involvement of at least 2 mucosal sites including the oral cavity and ocular surface. We analyzed HLA-A, -B, and -C of 131 CM-SJS/TEN patients and 419 Japanese controls.
HLA-A*02:06 was strongly associated with CM-SJS/TEN with SOC (carrier frequency: p=2.8X10-16, Pc=4.8X10-15, OR=5.7), and the odds ratio was highest for acetaminophen-related SJS/TEN with SOC (carrier frequency: p=5.0X10-13, Pc=8.5X10-12, OR=7.0).
Elucidating the predisposition to drug-induced severe cutaneous adverse reactions might make it possible to prevent drug-induced severe cutaneous adverse reactions with avoiding the risk drug from the person having the predisposition.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.